About this Medicine article
FDA Approves Perjeta (Pertuzumab) for Neoadjuvant Breast Cancer is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Publisher
- Lippincott Williams and Wilkins; Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins; Ovid Technologies (Wolters Kluwer Health) (ISSN 0276-2234)
- Published
- 2013
- Language
- EN
- Field
- Medicine (Health Sciences)